Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaos Corporation (DAC) vs Heron Therapeutics Inc (HRTX) Price & Performance

Danaos CorporationTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Danaos Corporation vs Heron Therapeutics Inc — how do they compare? Danaos Corporation trades at $138.27 (market cap $2.46B), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Danaos Corporation is far larger — about 40× Heron Therapeutics Inc's market cap, and Danaos Corporation pays a 2.67% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

DACHRTX
Market Cap
$2.46B$61.47M
Sector
TechnologyHealth
52-Week High
$143.15$1.49
52-Week Low
$84.05$0.32
Enterprise Value
$2.44B$168.21M
Dividend Yield
2.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaos Corporation

Danaos Corporation (DAC) trades at $137.35, down 0.7% on the day, but maintains strong technical and fundamental momentum. The stock shows a bullish technical signal with key support at $133 and resistance at $138. Fundamentally, DAC demonstrates exceptional profitability with a 51.26% net income margin and attractive valuation metrics including a P/E of 4.57 and P/B of 0.61. Recent Q2 2026 earnings beat expectations with EPS of $7.29 versus $6.80 expected, continuing a pattern of strong quarterly performance.

DAC presents a compelling value opportunity with deep discount to book value and consistent earnings outperformance. The company's record $4.6 billion contracted revenue backlog provides visibility, while quarterly dividends of $0.90 per share enhance shareholder returns. Primary risks include shipping industry cyclicality and capital expenditure requirements for fleet expansion. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's value proposition balanced against sector dynamics.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Danaos Corporation

Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.

Read more on DAC

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX